Transfer-pricing treatment of ITeS margins excludes pass-through tax recoveries and separate delayed-receivables interest after working-capital adjust...
Capacity-utilisation adjustments under TNMM can neutralise substantiated COVID-related idle costs where underutilisation materially affects profitabil...
TNMM functional comparability requires excluding rice manufacturers from a pure Basmati rice trader's benchmark and recognising operating export recei...
Working-capital adjustment subsumes delayed-receivable effects in TNMM benchmarking of captive software-development services, avoiding separate notion...
Transfer-pricing comparability requires exclusion of financially illogical super-profit comparables and correction of unsupported annual-report and ma...
Charitable character assessment preserves Section 80G approval despite inclusive spiritual teachings and incidental religious expenditure within the s...
Penalty proceedings for cash-loan acceptance require assessment proceedings and recorded Assessing Officer satisfaction; absent these, the proceedings...
Page of 4828
Press 'Enter' after typing page number.
161 to 180 of 96556 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Deduction for capital expenditure on scientific research under...
Pre-commencement R&D deduction denied where business had not commenced; deeming benefit requires tangible start of manufacture or commercial exploitation.
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Note: It is a system-generated summary and is for quick reference only.